We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
+27.77%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$1.42B
AUM Growth
+$256M
(+22%)
Cap. Flow
+$65.4M
Cap. Flow
% of AUM
4.61%
Top 10 Holdings %
Top 10 Hldgs %
29.29%
Holding
112
New
24
Increased
30
Reduced
36
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Atea Pharmaceuticals
AVIR
|
+$48.1M |
| 2 |
Replimune Group
REPL
|
+$27.8M |
| 3 |
Maravai LifeSciences
MRVI
|
+$27.3M |
| 4 |
Tandem Diabetes Care
TNDM
|
+$25.6M |
| 5 |
Certara
CERT
|
+$22.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMMU
Immunomedics Inc
IMMU
|
+$51M |
| 2 |
HMSY
HMS Holdings Corp.
HMSY
|
+$18.7M |
| 3 |
Zentalis Pharmaceuticals
ZNTL
|
+$18.2M |
| 4 |
Aprea Therapeutics
APRE
|
+$17.9M |
| 5 |
BPMC
Blueprint Medicines
BPMC
|
+$16.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.8% |
| 2 | Industrials | 1.99% |
| 3 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Atea Pharmaceuticals
AVIR
$379M
| $62.3M | 4.39% |
+1,492,090
| New | +$48.1M |
|
2
Arvinas
ARVN
$518M
| $45.2M | 3.18% |
532,125
-169,387
| -24% | -$5.84M |
|
|
3
Tandem Diabetes Care
TNDM
$1.17B
| $45.1M | 3.18% |
471,818
+248,850
| +112% | +$25.6M |
|
4
Teladoc Health
TDOC
$1.58B
| $42M | 2.96% |
209,859
+93,520
| +80% | +$19M |
|
5
Labcorp
LH
$24.3B
| $41.2M | 2.9% |
235,404
+32,156
| +16% | +$5.55M |
|
6
PTC Therapeutics
PTCT
$6.37B
| $36.9M | 2.6% |
603,978
-65,600
| -10% | -$3.87M |
|
7
Exelixis
EXEL
$13.9B
| $36.2M | 2.55% |
1,802,270
+945,500
| +110% | +$19.8M |
|
8
AtriCure
ATRC
$1.77B
| $35.9M | 2.53% |
644,217
-64,500
| -9% | -$2.79M |
|
9
Teleflex
TFX
$5.85B
| $35.5M | 2.5% |
86,193
+13,675
| +19% | +$5.05M |
|
|
FOLD
10
DELISTED
Amicus Therapeutics
FOLD
| $35.4M | 2.5% |
1,534,604
-619,029
| -29% | -$12.7M |
|
11
Acadia Pharmaceuticals
ACAD
$4.25B
| $35M | 2.47% |
654,414
+97,900
| +18% | +$4.86M |
|
|
PPD
12
DELISTED
PPD, Inc. Common Stock
PPD
| $33.4M | 2.36% |
977,154
+14,100
| +1% | +$493K |
|
13
Evolent Health
EVH
$475M
| $32.8M | 2.31% |
2,048,257
-38,178
| -2% | -$505K |
|
|
TPTX
14
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $31.4M | 2.21% |
257,379
+6,898
| +3% | +$756K |
|
|
AFIB
15
DELISTED
Acutus Medical Inc
AFIB
| $28.3M | 1.99% |
982,236
+450,078
| +85% | +$12.2M |
|
|
RCM
16
DELISTED
R1 RCM Inc. Common Stock
RCM
| $28.2M | 1.99% |
1,174,393
-366,000
| -24% | -$7.28M |
|
|
DCPH
17
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $27.9M | 1.97% |
488,842
+72,783
| +17% | +$4.31M |
|
|
18
Maravai LifeSciences
MRVI
$997M
| $27.4M | 1.93% |
+978,600
| New | +$27.3M |
|
|
19
Replimune Group
REPL
$814M
| $25.5M | 1.8% |
+667,729
| New | +$27.8M |
|
20
iRhythm Holdings
IRTC
$3.59B
| $25.3M | 1.78% |
106,565
+3,000
| +3% | +$684K |
|
|
SILK
21
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $25.2M | 1.77% |
399,483
+11,500
| +3% | +$713K |
|
22
Novavax
NVAX
$1.23B
| $24.9M | 1.76% |
223,350
+105,150
| +89% | +$11.2M |
|
23
Align Technology
ALGN
$12B
| $24.7M | 1.74% |
46,150
+9,850
| +27% | +$4.43M |
|
|
ARNA
24
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $24.6M | 1.73% |
320,059
-89,846
| -22% | -$6.73M |
|
25
Repligen
RGEN
$7.44B
| $23.8M | 1.68% |
124,193
+22,200
| +22% | +$4.04M |
|
Similar funds
RIP
LFWA
CF
WIM
MW
AFC
AAA
TGM
Sectoral Asset Management's Q4 2020 Portfolio in Review
As of Q4 2020, Sectoral Asset Management held 112 positions worth $1.42B, up 22% from $1.16B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Sectoral Asset Management deployed $65.4M of net new capital in Q4 2020, opening 24 new positions and adding to 30 existing holdings. Its largest new stake was Atea Pharmaceuticals: 1,492,090 shares worth $62.3M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 90% a quarter earlier, followed by Industrials and Technology.
On the sell side, the largest reduction was Aprea Therapeutics, an estimated $17.9M trimmed.
- Sectoral Asset Management's largest Q4 2020 buy was Atea Pharmaceuticals: 1,492,090 shares worth $62.3M.
- Sectoral Asset Management added most to Tandem Diabetes Care in Q4 2020, an estimated $25.6M increase.
- Sectoral Asset Management's biggest Q4 2020 reduction was Aprea Therapeutics, cutting an estimated $17.9M.
- Sectoral Asset Management fully exited Immunomedics Inc in Q4 2020, selling an estimated $51M.
- Sectoral Asset Management's ten largest holdings make up 29% of its $1.42B portfolio in Q4 2020.
- Sectoral Asset Management opened 24 new positions and closed 15 in Q4 2020.
- Sectoral Asset Management's portfolio value rose 22% quarter-over-quarter to $1.42B.
Based on Sectoral Asset Management's 13F filing for Q4 2020, filed 12 Feb 2021.